Early Olezarsen Therapy: A leap in triglyceride management
New study findings unveil Olezarsen’s potential to halve triglyceride levels with minimal side effects.
Topline:
The recent phase 2b trial of Olezarsen, an antisense therapy, demonstrates a significant reduction in triglycerides by approximately 50%, presenting a promising new treatment avenue for patients with elevated cardiovascular risks and healthcare providers looking for effective management options.
Study Details:
The Olezarsen study, termed BRIDGE-TI…
Keep reading with a 7-day free trial
Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.